In 2022, the centralized procurement of proprietary Chinese medicines will start in an all-round way!

 The centralized procurement of Chinese patent medicines is the general trend.
The completed centralized procurement of traditional Chinese patent medicines by Hubei Alliance and Guangdong Alliance will provide important references for the subsequent possible national procurement of Chinese patent medicines and other inter-provincial alliances
.
It is understood that a week later, the centralized procurement of 76 large varieties of Chinese patent medicines in 19 provinces including Hubei will be launched
.
Several notices have been issued recently
.
For example, on April 18, the Tibet Autonomous Region Medical Insurance Bureau issued the "Notice on Carrying out the Work Related to the Procurement of Selected Varieties by the Inter-Provincial Alliance of Chinese Patent Medicines", which pointed out that the implementation time for the centralized purchase of Chinese Patent Medicine Alliance in Hubei and other 19 provinces in Tibet Autonomous Region will be 2022.
On May 1, 2022, the maintenance time of product information and distribution relationship is from April 18 to April 25, 2022, and the time for signing the tripartite agreement is from April 26 to April 30, 2022
.
In addition, on the same day, the Henan Provincial Medical Insurance Bureau issued the "Notice on the Announcement of the Purchase Volume Data of Some Selected Varieties in Our Province", and announced the procurement volume data agreed by the Henan Provincial Pharmaceutical Institutions for the centralized procurement of Hubei Chinese Patent Medicine Alliance
.
The centralized procurement of the Chinese patent medicine alliance is constantly advancing.
It is reported that in addition to the centralized procurement of the Chinese patent medicine alliance in 19 provinces including Hubei, the results of the proposed selection of 53 large varieties of the Chinese patent medicine alliance in six provinces including Guangdong have been announced
.
It is understood that Hubei Alliance’s centralized procurement of proprietary Chinese medicines involves 76 major varieties, 182 products from 157 companies participated in the quotation, and the procurement scale was nearly 10 billion yuan; in the end, 97 companies and 111 products were selected, with a selection rate of 62% and a selected price.
The average decline was 42.
27%, and the largest decline was 82.
63%
.
Guangdong Alliance’s centralized procurement of proprietary Chinese medicines involved 53 major varieties, 87.
86% of the enterprises participated, and 86.
88% of the products produced quotations.
In the end, 361 products of 174 enterprises were to be selected/replaced, and the price of the exclusive varieties to be won was relatively small, with an average of 20% about 67.
8% for non-exclusive bid-winning products
.
According to the industry, it can be clearly felt that the promotion of the centralized procurement policy of proprietary Chinese medicines has accelerated since the beginning of this year.

.
It is reported that in order to implement the requirement of "speeding up and expanding coverage" for centralized procurement with volume, the National Medical Insurance Bureau has recently made a unified deployment and coordination for the centralized procurement of local alliances, and it is clarified that by the end of 2022, all provinces (including inter-provincial alliances) will carry out their own centralized procurement.
The total number of drug varieties collected is not less than 100, and must include chemical drugs, proprietary Chinese medicines, orthopedic trauma, oral implants, drug balloons and other consumables
.
That is to say, in 2022, all provinces will need to carry out the centralized procurement of Chinese patent medicines, and the procurement of Chinese patent medicines will start in an all-round way
.
The centralized procurement of Chinese patent medicines has a great impact on the market and enterprises.
For example, 19 provinces such as Hubei and 6 provinces such as Guangdong have included more than 20 provinces in the centralized procurement of Chinese patent medicines, and the participating areas cover nearly half of China
.
However, Chinese patent medicine products will be rapidly differentiated, and centralized procurement will not only test the production capacity of pharmaceutical companies, but also test the cost control ability and flexibility of price reduction of pharmaceutical companies
.
After Chinese patent medicine companies enter the alliance centralized procurement, they can change their promotion strategies if they want to develop better in the future
.
In addition, it is also crucial to develop new varieties and improve the decline in sales of old varieties due to centralized procurement
.
Under the promotion of the policy, Chinese medicine may be the focus of the alliance's centralized procurement, including Chinese patent medicine, Chinese medicine decoction pieces and formula granules
.
Under the normalization and institutionalization of centralized procurement, it is time for the transformation and upgrading of Chinese patent medicine enterprises
.
It is of great significance to strengthen the innovative research and development of traditional Chinese medicine in the future
.
It is understood that in recent years, the innovative research and development of traditional Chinese medicine has attracted much attention.
According to the data of the Drug Evaluation Center of the State Drug Administration, 27 new traditional Chinese medicines will be approved for approval in 2020, 62 new traditional Chinese medicines will be approved in 2021, and traditional Chinese medicines will be approved by the end of March in 2022.
The number of new drug approvals has reached 18, and the quality and growth rate of innovative research and development of traditional Chinese medicine has been improved
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.